Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

Cancer Immunology, Immunotherapy

Volumn 59, Issue 6, 2010, Pages 829-839

  Von Lilienfeld Toal, Marie ^a,b   Frank, Susanne ^b   Leyendecker, Christiane ^b   Feyler, Sylvia ^a   Jarmin, Sarah ^a   Morgan, Ruth ^a   Glasmacher, Axel ^b   Märten, Angela ^c   Schmidt Wolf, Ingo G H ^b   Brossart, Peter ^b   Cook, Gordon ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Immune escape; Innate immunity; MGUS; MICA; Multiple myeloma; NKG2D

Indexed keywords

HLA A ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSFORMING GROWTH FACTOR BETA; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRAIN K 562; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INCUBATION TIME; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MEMBRANE BINDING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BIOSYNTHESIS; BLOOD; CYTOTOXICITY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR ESCAPE;

ADULT; AGED; AGED, 80 AND OVER; CD8-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; KILLER CELLS, NATURAL; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TUMOR ESCAPE;

EID: 77953111633     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0807-3     Document Type: Article

References (33)

1. SJ Harrison G Cook 2005 Immunotherapy in multiple myeloma-possibility or probability? Br J Haematol 130 344 362 10.1111/j.1365-2141.2005.05534.x 1:CAS:528:DC%2BD2MXhtVWjsLvF 16042684 (Pubitemid 43899583)
2. G Cook JD Campbell CE Carr KS Boyd IM Franklin 1999 Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes J Leukoc Biol 66 981 988 1:CAS:528: DC%2BD3cXlsFak 10614781
3. RD Brown B Pope A Murray W Esdale DM Sze J Gibson PJ Ho D Hart D Joshua 2001 Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10 Blood 98 2992 2998 10.1182/blood.V98.10.2992 1:CAS:528:DC%2BD3MXosFynsbg%3D 11698282
4. M Beyer M Kochanek T Giese E Endl MR Weihrauch PA Knolle S Classen JL Schultze 2006 In vivo peripheral expansion of naive CD4+ CD25high FoxP3+ regulatory T cells in patients with multiple myeloma Blood 107 3940 3949 10.1182/blood-2005-09-3671 1:CAS:528:DC%2BD28XkvFWhu74%3D 16410445 (Pubitemid 43726800)
5. V Jurisic T Srdic G Konjevic O Markovic M Colovic 2007 Clinical stage-depending decrease of NK cell activity in multiple myeloma patients Med Oncol 24 312 317 10.1007/s12032-007-0007-y 17873307 (Pubitemid 350135953)
6. C Fauriat F Mallet D Olive RT Costello 2006 Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma Leukemia 20 732 733 10.1038/sj.leu.2404096 1:CAS:528:DC%2BD28XivVykurw%3D 16437151
7. E Carbone P Neri M Mesuraca MT Fulciniti T Otsuki D Pende V Groh T Spies G Pollio D Cosman, et al. 2005 HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells Blood 105 251 258 10.1182/blood-2004-04-1422 1:CAS:528:DC%2BD2MXis1Gquw%3D%3D 15328155 (Pubitemid 40053090)
8. S Girlanda C Fortis D Belloni E Ferrero P Ticozzi C Sciorati M Tresoldi A Vicari T Spies V Groh, et al. 2005 MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes Cancer Res 65 7502 7508 10.1158/0008-5472.CAN-05-0731 1:CAS:528:DC%2BD2MXns1Wqs7o%3D 16103105 (Pubitemid 41161286)
9. YM El-Sherbiny JL Meade TD Holmes D McGonagle SL Mackie AW Morgan G Cook S Feyler SJ Richards FE Davies, et al. 2007 The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells Cancer Res 67 8444 8449 10.1158/0008-5472.CAN-06-4230 1:CAS:528:DC%2BD2sXhtVCit7zN 17875681 (Pubitemid 47437416)
10. PK Epling-Burnette F Bai JS Painter DE Rollison HR Salih M Krusch J Zou E Ku B Zhong D Boulware, et al. 2007 Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors Blood 109 4816 4824 10.1182/blood-2006-07-035519 1:CAS:528:DC%2BD2sXmt1Oguro%3D 17341666 (Pubitemid 46827777)
11. T Osaki H Saito T Yoshikawa S Matsumoto S Tatebe S Tsujitani M Ikeguchi 2007 Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer Clin Cancer Res 13 382 387 10.1158/1078-0432.CCR- 06-1454 1:CAS:528:DC%2BD2sXoslSmsw%3D%3D 17255258 (Pubitemid 46225340)
12. JC Lee KM Lee DW Kim DS Heo 2004 Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients J Immunol 172 7335 7340 1:CAS:528:DC%2BD2cXks1ahtbw%3D 15187109
13. V Groh J Wu C Yee T Spies 2002 Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 419 734 738 10.1038/nature01112 1:CAS:528:DC%2BD38XnvVyrt7o%3D 12384702 (Pubitemid 35177960)
14. ES Doubrovina MM Doubrovin E Vider RB Sisson RJ O'Reilly B Dupont YM Vyas 2003 Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma J Immunol 171 6891 6899 1:CAS:528: DC%2BD3sXpsV2rur0%3D 14662896
15. HR Salih H Antropius F Gieseke SZ Lutz L Kanz HG Rammensee A Steinle 2003 Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia Blood 102 1389 1396 10.1182/blood-2003-01-0019 1:CAS:528:DC%2BD3sXmsFWkt7w%3D 12714493 (Pubitemid 36988048)
16. A Märten M von Lilienfeld-Toal MW Buchler J Schmidt 2006 Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity Int J Cancer 119 2359 2365 10.1002/ijc.22186 16929491 (Pubitemid 44546956)
17. V Rebmann P Schutt D Brandhorst B Opalka T Moritz MR Nowrousian H Grosse-Wilde 2007 Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients Clin Immunol 123 114 120 10.1016/j.clim.2006.11.007 1:CAS:528:DC%2BD2sXjtValtLw%3D 17218152 (Pubitemid 46401507)
18. M Jinushi M Vanneman NC Munshi YT Tai RH Prabhala J Ritz D Neuberg KC Anderson DR Carrasco G Dranoff 2008 MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma Proc Natl Acad Sci USA 105 1285 1290 10.1073/pnas.0711293105 1:CAS:528:DC%2BD1cXhs1Kmu78%3D 18202175 (Pubitemid 351397045)
19. RA Kyle SV Rajkumar 2007 Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression Br J Haematol 139 730 743 10.1111/j.1365-2141.2007.06873.x 1:CAS:528:DC%2BD1cXhs12gtbg%3D 18021088 (Pubitemid 350115735)
20. AC Rawstron FE Davies R DasGupta AJ Ashcroft R Patmore MT Drayson RG Owen AS Jack JA Child GJ Morgan 2002 Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation Blood 100 3095 3100 10.1182/blood-2001-12-0297 1:CAS:528:DC%2BD38XosVSis7s%3D 12384404 (Pubitemid 35217054)
21. C Vitale L Chiossone C Cantoni G Morreale F Cottalasso S Moretti A Pistorio R Haupt E Lanino G Dini, et al. 2004 The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity Eur J Immunol 34 3028 3038 10.1002/eji.200425418 1:CAS:528:DC%2BD2cXhtVWisrfO 15368269 (Pubitemid 39549382)
22. S Holdenrieder P Stieber A Peterfi D Nagel A Steinle HR Salih 2006 Soluble MICA in malignant diseases Int J Cancer 118 684 687 10.1002/ijc.21382 1:CAS:528:DC%2BD28XjvFOrtQ%3D%3D 16094621 (Pubitemid 43076018)
23. J Sugita J Tanaka A Yasumoto S Shiratori K Wakasa M Kikuchi A Shigematsu T Kondo M Asaka M Imamura 2009 Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8(+) T cells Ann Hematol 4 4
24. N Boissel D Rea V Tieng N Dulphy M Brun JM Cayuela P Rousselot R Tamouza P Le Bouteiller FX Mahon, et al. 2006 BCR/ABL oncogene directly controls MHC class I chain-related molecule. A expression in chronic myelogenous leukemia J Immunol 176 5108 5116 1:CAS:528:DC%2BD28XjtV2gtLk%3D 16585609
25. SJ Burgess AI Marusina I Pathmanathan F Borrego JE Coligan 2006 IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8 + T cells J Immunol 176 1490 1497 1:CAS:528:DC%2BD28XlsFygsw%3D%3D 16424177
26. HG Kopp T Placke HR Salih 2009 Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity Cancer Res 69 7775 7783 10.1158/0008-5472.CAN-09-2123 1:CAS:528:DC%2BD1MXht1Skt7nP 19738039
27. B Suarez-Alvarez A Lopez-Vazquez B Diaz-Molina MJ Bernardo-Rodriguez R Alvarez-Lopez D Pascual A Astudillo J Martinez-Borra JL Lambert S Gonzalez, et al. 2006 The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection Transplantation 82 354 361 10.1097/01.tp.0000228911.22944.23 1:CAS:528:DC%2BD28XotVWktr8%3D 16906033 (Pubitemid 44223034)
28. K Wiemann HW Mittrucker U Feger SA Welte WM Yokoyama T Spies HG Rammensee A Steinle 2005 Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo J Immunol 175 720 729 1:CAS:528:DC%2BD2MXlvFSjsLw%3D 16002667
29. DE Oppenheim SJ Roberts SL Clarke R Filler JM Lewis RE Tigelaar M Girardi AC Hayday 2005 Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance Nat Immunol 6 928 937 10.1038/ni1239 1:CAS:528: DC%2BD2MXos1eqtL0%3D 16116470 (Pubitemid 43090448)
30. M Kloss P Decker KM Baltz T Baessler G Jung HG Rammensee A Steinle M Krusch HR Salih 2008 Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA J Immunol 181 6711 6719 1:CAS:528:DC%2BD1cXhtlaisr7F 18981088
31. C Cerboni M Ardolino A Santoni A Zingoni 2009 Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells Blood 113 2955 2964 10.1182/blood-2008-06-165944 1:CAS:528:DC%2BD1MXktFWnsbg%3D 19124832
32. JY Kim JH Bae SH Lee EY Lee BS Chung SH Kim CD Kang 2008 Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide J Immunother 31 475 486 10.1097/CJI.0b013e3181755deb 1:CAS:528:DC%2BD1cXmsFyrs7o%3D 18463537
33. A Poggi S Catellani A Garuti I Pierri M Gobbi MR Zocchi 2009 Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate Leukemia 23 641 648 10.1038/leu.2008.354 1:CAS:528:DC%2BD1MXks1SitLY%3D 19151770